Literature DB >> 28464965

Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study.

H L Alderson1, D M Semple2, C Blayney3, F Queirazza4, V Chekuri2, S M Lawrie5.   

Abstract

BACKGROUND: The potential for drugs of abuse to induce acute psychotic symptoms is well recognised. However, the likelihood of transition from initial substance-induced psychotic disorder (SIPD) to chronic psychosis is much less well understood. This study investigated the rate of SIPD transition to schizophrenia (F20), the time to conversion and other possible related factors.
METHODS: Using data from the Scottish Morbidity Record, we examined all patients (n = 3486) since their first admission to psychiatric hospital with a diagnosis of SIPD [International Classification of Diseases, Tenth Revision (ICD-10) codes F10-F19, with third digit five] from January 1997 to July 2012. Patients were followed until first episode of schizophrenia (ICD-10 code F20, with any third digit) or July 2012. Any change in diagnosis was noted in the follow-up period, which ranged from 1 day to 15.5 years across the groups.
RESULTS: The 15.5-year cumulative hazard rate was 17.3% (s.e. = 0.007) for a diagnosis of schizophrenia. Cannabis, stimulant, opiate and multiple drug-induced psychotic disorder were all associated with similar hazard rates. The mean time to transition to a diagnosis of schizophrenia was around 13 years, although over 50% did so within 2 years and over 80% of cases presented within 5 years of SIPD diagnosis. Risk factors included male gender, younger age and longer first admission.
CONCLUSIONS: SIPD episodes requiring hospital admission for more than 2 weeks are more likely to be associated with later diagnosis of schizophrenia. Follow-up periods of more than 2 years are needed to detect the majority of those individuals who will ultimately develop schizophrenia.

Entities:  

Keywords:  Chronic psychosis; psychosis; schizophrenia; substance-induced psychotic disorder

Mesh:

Year:  2017        PMID: 28464965     DOI: 10.1017/S0033291717001118

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   10.592


  11 in total

Review 1.  Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates.

Authors:  Christopher J Hammond; Aldorian Chaney; Brian Hendrickson; Pravesh Sharma
Journal:  Int Rev Psychiatry       Date:  2020-02-06

2.  Contact with mental health services in the 12-month period before offending in a cohort of forensic order patients.

Authors:  Bob Green; Megan L Steele; Fiona Davidson; Darren Neillie
Journal:  Psychiatr Psychol Law       Date:  2021-04-09

3.  Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Authors:  Kenneth S Kendler; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

4.  Predicting one-year outcome in first episode psychosis using machine learning.

Authors:  Samuel P Leighton; Rajeev Krishnadas; Kelly Chung; Alison Blair; Susie Brown; Suzy Clark; Kathryn Sowerbutts; Matthias Schwannauer; Jonathan Cavanagh; Andrew I Gumley
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

5.  Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Benjamin Murrie; Julia Lappin; Matthew Large; Grant Sara
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 6.  Cannabis and Psychosis Through the Lens of DSM-5.

Authors:  Nathan T Pearson; James H Berry
Journal:  Int J Environ Res Public Health       Date:  2019-10-28       Impact factor: 3.390

7.  First episode psychosis: register-based study of comorbid psychiatric disorders and medications before and after.

Authors:  Pontus Strålin; Jerker Hetta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-26       Impact factor: 5.270

Review 8.  A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.

Authors:  Travis A Wearne; Jennifer L Cornish
Journal:  Front Psychiatry       Date:  2018-10-10       Impact factor: 4.157

9.  Opioid-Induced Psychosis in a Patient With Sickle Cell Disease.

Authors:  Terence Tumenta; Amod Thanju; Pradilka Perera; Jisha Kallikkadan; Patrice Fouron; Tolulope Olupona
Journal:  Cureus       Date:  2021-06-09

Review 10.  [Differential diagnostic distinction between substance-induced and primary psychoses: : Recommendations for general psychiatric and forensic practice].

Authors:  Dusan Hirjak; Andreas Meyer-Lindenberg; Geva A Brandt; Harald Dreßing
Journal:  Nervenarzt       Date:  2021-03-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.